Analysts who follow Inovio Pharmaceuticals Inc (INO) on average expect it to rise 96.95% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns the stock an Analyst Ranking of 31, which means it ranks higher than 31 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating INO a Buy today. Find out what this means to you and get the rest of the rankings on INO!